MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Ribavirin
CAS No. : 36791-04-5
MCE 国际站：Ribavirin
产品活性：Ribavirin (ICN-1229) 是广谱的抗病毒剂，可抑制 HCV，HIV，RSV 等病毒。Ribavirin 还具有抗正痘病毒 (orthopoxvirus) 和抗天花病毒活性。
研究领域：Anti-infection
作用靶点：HCV | RSV | Orthopoxvirus | Antibiotic
In Vitro: Treatmentof LPS-stimulated microglia with 5, 10 and 20 μM Ribavirin (ICN-1229) induces reduction of NO2 levels for 43% (p<0.05), 53% (p<0.05) and 59% (p<0.05), respectively. Ribavirin (ICN-1229) (10 mM) insignificantly decreases the cell surface area in non-stimulated culture, but significantly reduces cell surface area (by 32%, p<0.05) in LPS-stimulated microglia. Ribavirin (ICN-1229) is active against DENV, with an EC50 of 3 μM in A549 cells, and combination of CM-10-18 with Ribavirin (ICN-1229) demonstrates a clear enhancement in the reduction of virus replication.
In Vivo: ALT, AST activities and bilirubin levels are significantly loared by administration of JAT in combination with interferon and Ribavirin (ICN-1229) (p<0.01). JAT, interferon or ribavirin alone with CCl4, livers appear to exhibit some liver protection against CCl4 as evident by the presence of normal hepatic cords, absence of necrosis and lesser fatty infiltration. Groups treated with JAT, Peg-interferon and Ribavirin (ICN-1229) separately or in combination shows reduction in the expression of TGF- β and Bax. In the group treated by triple combination of interferon, Ribavirin (ICN-1229), and JAT, the expression level of p53 is markedly reduced.
Ribavirin (ICN-1229) capsules (400 mg of ribavirin)-treated Wistar rats show a significant decrease in activin-A and significant increase in follistatin at the serum and liver levels. Ribavirin (ICN-1229) has strong antiviral activity only when ribavirin is combined with either IFN-α or Peg-IFN-α.
Ribavirin (40 mg/kg, p.o.) significantly improves the antiviral efficacy of CM-10-18 in mice. Ribavirin (ICN-1229) inhibits DENV virus infection in cultured cells, but it is ineffective in reducing viremia in monotherapy.
相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Antiviral Compound Library | CNS-Penetrant Compound Library | Drug Repurposing Compound Library | Nucleotide Compound Library | Anti-COVID-19 Compound Library | NMPA-Approved Drug Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Antibiotics Library | Anti-Hepatitis C Virus Compound Library | Drug-Induced Liver Injury (DILI) Compound Library | Rare Diseases Drug Library | Children’s Drug Library | EMA-Approved Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Orthopoxvirus Compound Library | Off-patent Drug Library | Multi-Target Compound Library | Bioactive Compound Library Max | Rapamycin | Cycloheximide | Chloroquine | Doxorubicin hydrochloride | Bafilomycin A1 | Dexamethasone | Staurosporine | Actinomycin D | Puromycin dihydrochloride | Etoposide | Brefeldin A | Cyclosporin A | Nigericin sodium salt | G-418 disulfate | 5-Azacytidine | Resiquimod | Bleomycin sulfate | Hygromycin B | Mitomycin C | Ionomycin | Resveratrol | Cytarabine | Tunicamycin | Doxycycline | Tacrolimus | Oligomycin | Streptozotocin | Neomycin sulfate
热门产品线：重组蛋白 | 药物筛选 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
• 提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。
